Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 31, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details a specific change in the shareholding of the GlaxoSmithKline US Retirement Savings Plan ("the Plan"):
- Date of Movement: July 28, 2006
- Previous Holdings: 17,298,647 Ordinary Share ADRs
- New Holdings: 17,338,911 Ordinary Share ADRs
- Average Price: $55.28
- Reason: A movement in the fund.
Directors Dr. J.P. Garnier and Dr. M.M. Slaoui are noted as potentially interested in these shares as beneficiaries of the discretionary fund, alongside other employees and former employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly limited to the notification of the transaction described above in accordance with Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Verify the total number of ADRs held by the US Retirement Savings Plan increased by 40,264 shares.
- Confirm the average transaction price of $55.28 per ADR.
- Note that the change was driven by fund movements rather than direct trading by the named directors.
- Understand that this filing does not contain financial performance data for the period.